*Refresh the page if the below document does not appear.
Pharma companies opposes Govt plan to ban Codeine based cough syrups
IDMA (Indian Drug Manufacturer’s Association) has asked the authorities to not move ahead with the proposed ban informing that these are very common among medical professionals to treat a number of ailments.
Natco Pharma launches NATGEN in the Indian Market
The company informed the exchanges of its newly launched formulation of Chlorantraniliprole (CTPR) 18.5% SC under the brand name NATGEN. The CTPR formulated products are estimated to have a market size of over ₹2000 crores in India.
Cancer medicines predicted to get cheaper in the future with ATOM initiative
UICC (Union for International Cancer Control) has launched an initiative called ATOM (Access to Oncology Medicines) which aims to provide access to quality Cancer healthcare among the 170 odd member countries of the Union including India.
AFDIL drugs to focus on speciality therapeutic segments
Anglo-French Drugs & Industries has started working to build its business again following the sale of its brands to Lupin. The company’s president said that the key focus is on specialty segments like orthopedics, women’s health, respiratory, and insomnia including non-branded generics.
GSK appoints Julie Brown as its first female CFO
Britain-based company recently appointed its first female Chief Financial Officer after Iain Mackay as it continues to focus on its core pharmaceuticals business. The new CFO is expected to join in April.
Biogen accused of bribing doctors to promote their product
The US pharma company has reached a $900 Million settlement with the informant who accused the firm to have paid millions of dollars to doctors to persuade them into prescribing their medicine Avonex and Tysabri for multiple sclerosis treatment.
Some big pharma companies to suffer from President Biden's pricing bill
Analysts from morningstar after analyzing the
data have stated that new initiatives will
decrease the revenue of companies by overall
2%. However, some companies such as Novo
Nordisk, Gilead, Bristol Myers Squibb, AbbVie
and AstraZeneca experience the loss more
than other companies.
